342 related articles for article (PubMed ID: 8442109)
21. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
22. [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: "minitransplant"].
Gómez-Almaguer D; Ruiz-Argüelles GJ; González-Llano O; Ruiz-Argüelles A; Cantú-Rodríguez OG
Gac Med Mex; 2002; 138(3):235-9. PubMed ID: 12096391
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
25. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia.
Barrett AJ
Leukemia; 1992; 6 Suppl 2():139-43. PubMed ID: 1578917
[No Abstract] [Full Text] [Related]
30. Acute lymphoblastic leukemia; factors influencing relapse after allogeneic bone marrow transplantation.
Zwaan FE; Hermans J
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():71. PubMed ID: 2390643
[No Abstract] [Full Text] [Related]
31. Idarubicin plus ARA-C followed by allogeneic or autologous bone marrow transplantation in advanced acute lymphoblastic leukemia.
Arcese W; Meloni G; Giona F; Vegna ML; Testi AM; Annino L; Iori AP; Carotenuto M; Resegotti L; Madon E
Bone Marrow Transplant; 1991; 7 Suppl 2():38. PubMed ID: 1878711
[No Abstract] [Full Text] [Related]
32. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S; Lin HS; Dipersio J; Adkins D
Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow transplantation for leukemia after conditioning with busulfan and cyclophosphamide. Bone marrow morphology in the early recovery phase.
Cao DC; Tutschka PJ
Chin Med J (Engl); 1991 Apr; 104(4):267-76. PubMed ID: 2065543
[TBL] [Abstract][Full Text] [Related]
35. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT.
Uehara T; Nakaseko C; Yokota A; Saito Y; Nishimura M
Am J Hematol; 2002 Sep; 71(1):37-40. PubMed ID: 12221672
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
37. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
39. A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
Yoshihara T; Naya M; Tsunamoto K; Hojo M; Hibi S; Morimoto A; Todo S; Imashuku S
Anticancer Res; 2003; 23(2C):1739-42. PubMed ID: 12820450
[TBL] [Abstract][Full Text] [Related]
40. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
